KPC PharmaceuticalsInc Performance dei guadagni passati

Il passato criteri di controllo 4/6

Gli utili di KPC PharmaceuticalsInc sono diminuiti a un tasso medio annuo di -2.4%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 9.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 0.8%. Il ritorno sul capitale proprio di KPC PharmaceuticalsInc è 7.9% e ha margini netti di 5.9%.

Informazioni chiave

-2.4%

Tasso di crescita degli utili

-2.1%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	10.9%
Tasso di crescita dei ricavi	-0.8%
Rendimento del capitale proprio	7.9%
Margine netto	5.9%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Nov 18

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Sep 30

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Sep 11

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Jul 25

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

Jun 25

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

Jun 04

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Mar 28

Ripartizione dei ricavi e delle spese

Come KPC PharmaceuticalsInc guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

SHSE:600422 Ricavi, spese e utili (CNY Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	7,550	446	2,474	88
30 Jun 24	7,487	451	2,575	79
31 Mar 24	7,646	432	2,705	72
31 Dec 23	7,703	445	2,791	71
30 Sep 23	7,700	397	2,737	39
30 Jun 23	7,825	390	2,815	46
31 Mar 23	7,828	400	2,852	57
31 Dec 22	8,282	383	2,851	70
30 Sep 22	8,419	446	2,865	102
30 Jun 22	8,388	392	2,825	108
31 Mar 22	8,722	427	2,821	104
31 Dec 21	8,254	508	2,815	101
30 Sep 21	8,321	540	2,806	140
30 Jun 21	8,386	564	2,874	139
31 Mar 21	8,045	560	2,834	145
01 Jan 21	7,717	457	2,672	128
30 Sep 20	7,779	445	2,952	103
30 Jun 20	7,788	444	2,990	93
31 Mar 20	7,910	443	3,094	79
31 Dec 19	8,120	454	3,337	84
30 Sep 19	7,817	429	3,226	77
30 Jun 19	7,473	390	3,159	83
31 Mar 19	7,237	356	3,062	77
31 Dec 18	7,102	336	3,000	83
30 Sep 18	6,797	316	2,842	70
30 Jun 18	6,507	295	2,641	90
31 Mar 18	6,280	318	2,379	83
31 Dec 17	5,852	330	2,130	63
30 Sep 17	5,637	357	1,936	40
30 Jun 17	5,330	374	1,746	0
31 Mar 17	5,170	416	1,618	0
31 Dec 16	5,101	407	1,519	0
30 Sep 16	5,161	440	1,295	0
30 Jun 16	5,227	448	1,304	0
31 Mar 16	5,049	433	1,224	0
31 Dec 15	4,916	421	1,177	0
30 Sep 15	4,588	404	1,076	0
30 Jun 15	4,456	367	983	0
31 Mar 15	4,361	308	990	0
31 Dec 14	4,316	289	931	0
30 Sep 14	4,038	264	904	0
30 Jun 14	3,860	258	830	0
31 Mar 14	3,668	243	725	0
31 Dec 13	3,584	232	728	0

Guadagni di qualità: 600422 ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di 600422 (5.9%) 600422 sono più alti rispetto allo scorso anno (5.1%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di 600422 sono diminuiti del 2.4% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di 600422 nell'ultimo anno ( 12.5% ) supera la media quinquennale ( -2.4% all'anno).

Guadagni vs Settore: La crescita degli utili 600422 nell'ultimo anno ( 12.5% ) ha superato la percentuale del settore Pharmaceuticals -2.5%.

KPC PharmaceuticalsInc Performance dei guadagni passati

Il passato criteri di controllo 4/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Recent updates

Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)

Third quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.22 in 3Q 2023)

KPC Pharmaceuticals,Inc. to Report Q3, 2024 Results on Oct 26, 2024

Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?

Investor sentiment improves as stock rises 20%

New minor risk - Earnings quality

These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 2Q 2023)

Investor sentiment deteriorates as stock falls 16%

KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20

Dividend increased to CN¥0.20

KPC Pharmaceuticals,Inc. to Report First Half, 2024 Results on Aug 23, 2024

Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)

We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt

KPC Pharmaceuticals,Inc, Annual General Meeting, Jun 21, 2024

Price target decreased by 7.1% to CN¥25.01

KPC Pharmaceuticals,Inc to Report Q1, 2024 Results on Apr 27, 2024

KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues

Full year 2023 earnings: EPS and revenues miss analyst expectations

KPC Pharmaceuticals,Inc to Report Fiscal Year 2023 Results on Mar 22, 2024

Third quarter 2023 earnings released

Investor sentiment improves as stock rises 16%

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 16%

KPC Pharmaceuticals,Inc to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.13 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.17 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.12 in 1Q 2020)

New Hope Healthcare Nanjing Investment Center (Limited Partnership) signed an agreement to acquire 3.7% stake in Nanjing Weili Zhibo Biotechnology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for CNY 30 million.

Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.60 in FY 2019)

New 90-day low: CN¥8.34

KPC Pharmaceuticals, Inc. to Report Fiscal Year 2020 Results on Mar 16, 2021

New 90-day low: CN¥8.38

New 90-day low: CN¥9.12

New 90-day low: CN¥9.54

Third quarter earnings released

KPC Pharmaceuticals, Inc. to Report Q3, 2020 Results on Oct 22, 2020

A group of buyers agreed to acquire 51% stake in Kunming Yinnuo Pharmaceutical Technology Co., Ltd. from KPC Pharmaceuticals, Inc. (SHSE:600422) for approximately CNY 170 million.

KPC Pharmaceuticals, Inc. (SHSE:600422) cancelled the acquisition of 30% stake in Zhejiang Holley Nanhu Pharmaceutical Co., Ltd.

First half earnings released

New 90-day high - CN¥11.67

KPC Pharmaceuticals, Inc. to Report First Half, 2020 Results on Aug 21, 2020

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate